Archives

by in
Entry Author Date Location
Third Rock Looks to Fight Fat in a New Way, With Ember Therapeutics 12/15/11 Boston
Xconomist of the Week: Larry Smarr’s Quest for ‘Quantified Health’ 11/22/11 San Diego
Rhythm Adds Former Merck VP as CEO 11/09/11 Boston
Editor’s Picks: Xconomy Boston’s Top 20 Stories of the Third Quarter 10/28/11 Boston
New Genzyme CEO, Biogen Scores in 2nd MS Pill Trial, Nanotech Drug Startups Nab Funds, & More Boston-Area Life Sciences News 10/28/11 Boston
MPM-Backed Rhythm Advances Drug Programs in Diabetes and Obesity 10/25/11 Boston
Orexigen’s Diet Drug Springs Back to Life, Independa Gets $1.6M, NuVasive Faces Big Judgments in Patent Dispute, & More San Diego Life Sciences News 09/22/11 San Diego
Orexigen Revives Obesity Drug After One More Go-Round With FDA 09/20/11 San Diego
Tensha Nabs $15M, Termeer Gives MIT $10M, Stata Puts $10M Into NABsys, & More Boston-Area Life Sciences News 09/16/11 Boston
GI Dynamics Starts Trading on Aussie Exchange, Eyes U.S. Pilot Study for Device in Diabetes and Obesity 09/14/11 Boston
Pfizer Grows in Cambridge, Repligen Eyes Imaging Approval, GI Dynamics Gets Aussie IPO, & More Boston-Area Life Sciences News 09/02/11 Boston
GI Dynamics Raises $85M USD in Aussie IPO 08/30/11 Boston
Vivus Adds $45.8M 08/23/11 San Francisco
Amylin & Takeda Halt Obesity Drug Development 08/04/11 San Diego
GI Dynamics and Exa File for IPOs in Weight Loss Devices, Automotive Software 08/04/11 Boston
Arena Passes Small Study, in Bid to Answer FDA Questions About Obesity Drug 08/02/11 San Diego
Compuware Scoops Up DynaTrace, Medtronic Buys Salient Surgical, Avedro Snaps Up $25M, & More Boston-Area Deals News 07/13/11 Boston
Rib-X Inks Sanofi Deal, Zafgen Gets $33M Series C, Allegro Adds $5.4M, & More Boston-Area Life Sciences News 07/08/11 Boston
Zafgen Pockets $33M To Take Obesity Drug Through Next Big Step in Clinical Trials 07/07/11 Boston
A San Diego Sampler from the War on Diabetes 06/24/11 San Diego
Orexigen, Facing High Hurdle at FDA, Puts Obesity Drug Development on Hold; Shares Tank 06/03/11 San Diego
Biotech’s Missed Opportunity: Small-Town and Rural America 04/18/11 National
Arena Adds $35.5M 03/29/11 San Diego
Amylin and Takeda Suspend Obesity Study to Consider Metreleptin Data 03/16/11 San Diego
Vivus to Try Again By Year’s End 02/28/11 San Francisco
Orexigen Axes 40 Percent of Workforce After FDA Turns Down Obesity Drug 02/09/11 San Diego
What’s Brewing at Massive Health? A Chat with Newly Funded Co-Founders Sutha Kamal and Aza Raskin 02/02/11 San Francisco
Orexigen Fails to Win FDA Approval of Obesity Drug, Stock Crashes 02/01/11 San Diego
San Diego’s Fight Against Diabesity: The Photo Gallery 01/28/11 San Diego
Arena Pharmaceuticals Axes One-Fourth of Workforce As it Hangs On With Obesity Drug 01/27/11 San Diego
Page 2 of 6 « previous page · next page »